CMP: INR 1,214 Target Price: INR 870 (INR 900) 🔻 -28%

09 August 2024

Alembic Pharma

Pharma

US at an inflection; margin recovery slower than anticipated

Alembic Pharma's (Alembic) Q1FY25 performance was below our expectation. US sales grew 9% QoQ (18.2% YoY), though the pain in other international markets (+1.9% YoY) and API's (-15.1%) dragged performance. Gross margins, at 74.8% were maintained QoQ, management guides for gross margins of ~70% ahead. R&D cost dipped -7.8% YoY in Q1 and supported margins. Full-year R&D guidance of INR 5.5bn (up 14% YoY) is retained. Alembic aims to launch ten new products in Q2FY25 (25+ in FY25), which shall drive 10–15% growth in US. India human formulation shall grow in single-digits. EBITDA margins may touch 18–20% in two years as asset utilisation improves. We cut FY25E/26E EPS by 3-5% due to slower recovery in margins. Downgrade to **SELL** on expensive valuation (30x FY26E EPS); TP revised to INR 870, based on 21x FY26E EPS.

US and India aid recovery in margins

Revenue for the quarter grew 5.1% YoY (+2.9% QoQ) to INR 15.6bn (I-Sec: INR 16.2bn) led by healthy growth in US and domestic formulation segment. Gross margin expanded 259bps YoY (-23bps QoQ) to 74.8% due to product mix improvement. EBITDA grew 19.2% YoY (-8.9% QoQ) to INR 2.4bn (I-Sec: INR 2.6bn). EBITDA margin expanded 180bps YoY (-198bps QoQ) to 15.2% (I-Sec: 16%). PAT grew 11.5% YoY (-24.5% QoQ) to INR 1.3bn (I-Sec: INR 1.5bn).

US outlook improving; challenges in India persist

US sales grew 18.2% YoY (+9% QoQ) to INR 4.6bn (USD 55mn). Alembic launched two new products in Q1 (cumulative count to 149 products) in the US market. It targets to launch 25 products in US in FY25E, which should drive US business growth of 10.4% CAGR over FY24–26E. R&D expense was 7% of sales in Q1FY25 at vs. 7.9%/8% in Q4FY24/Q1FY24; it expects R&D spending to rise to INR 5.5bn in FY25. India business growth stood at 9.2% YoY (+13.7% QoQ). Animal health segment rose 23% YoY led by basket of strong brands. Management is confident of outperforming IPM, excluding the animal health business. We expect India business to grow 7.6% over FY24–26E. Other international markets were up 1.9% YoY (+3.4% QoQ) to INR 2.7bn. API sales declined 15.1% YoY (-21.5% QoQ) to INR 2.6bn due to few customer-level shortfalls, FDA issue for one of its customer and pricing pressure.

Abdulkader Puranwala

abdulkader.puranwala@icicisecurities.com +91 22 6807 7339 **Nisha Shetty** nisha.shetty@icicisecurities.com

Market Data

Market Cap (INR)	239bn
Market Cap (USD)	2,842mn
Bloomberg Code	ALPM IN
Reuters Code	ALEM.BO
52-week Range (INR)	1,286 /707
Free Float (%)	28.0
ADTV-3M (mn) (USD)	4.7

Price Performance (%)	3m	6m	12m
Absolute	20.9	22.6	53.5
Relative to Sensex	13.6	12.1	33.7

Financial Summary

Y/E March (INR mn)	FY23A	FY24A	FY25E	FY26E
Net Revenue	56,526	62,286	67,840	74,048
EBITDA	7,083	9,334	10,990	13,032
EBITDA Margin (%)	12.5	15.0	16.2	17.6
Net Profit	3,420	6,158	6,500	8,215
EPS (INR)	17.4	31.3	33.1	41.8
EPS % Chg YoY	(37.3)	80.1	5.6	26.4
P/E (x)	69.8	38.7	36.7	29.0
EV/EBITDA (x)	34.4	25.9	21.7	18.0
RoCE (%)	7.7	12.9	12.4	14.3
RoE (%)	7.1	13.4	12.8	14.6

Earnings Revisions (%)	FY25E	FY26E
Revenue	(0.9)	(0.6)
EBITDA	(2.1)	(1.7)
EPS	(5.3)	(3.2)

Previous Reports

10-05-2024: Q4FY24 results review	N
06-02-2024: Q3FY24 results review	N



India | Equity Research | Q1FY25 results review



Valuation

Alembic's US business in Q1 benefited from lumpy sales of third-party products while its base portfolio continues to face double-digit erosion. Through its 25 new launches in FY25, the company will likely offset the impact of price erosion and drive 10–15% growth in FY25. In India, tepid performance in acute therapies has slowed down overall India growth, while traction in the animal health segment is being maintained.

Alembic's efforts to curtail R&D cost has aided the company in restoring its margin profile in the last couple of years. R&D rationalisation has led to massive savings of INR 2.4bn (506bps of margins), which Alembic has used to pare debt by INR 2.1bn in FY24. Ahead, its ability to control overhead costs will be critical in aiding margin expansion hereon.

We lower our FY25E/26E earnings by 5%/3%. We expect revenue/EBITDA/PAT at a CAGR of 9%/18.2%/15.5% for FY24–26E. The stock currently trades at 36.7x FY25E and 29x FY26E earnings; and EV/EBITDA multiples of 21.7x FY25E and 18x FY26E. We lower our rating to **SELL** (earlier Reduce) and target price to INR 870 (from INR 900), based on 21x FY26E EPS.

Key upside risks: Commercialisation of high-value launches; and moderation in overhead costs.

Exhibit 1: Quarterly review

YE 31 March (INR mn)	Q1FY25	Q1FY24	%YoY	Q4FY24	% QoQ	FY24	FY23	%YoY
Sales	15,617	14,862	5.1	15,170	2.9	62,286	56,526	10.2
Gross Profit	11,676	10,726	8.9	11,376	2.6	45,136	39,438	14.4
Gross Margin (%)	74.8	72.2	259bps	75.0	-23bps	72.5	69.8	270bps
Employee expenses	3,798	3,482	9.1	4,019	(5.5)	14,463	11,691	23.7
Other expenses	4,417	4,072	8.5	3,560	24.1	16,539	13,445	23.0
R&D exp	1,093	1,186	(7.8)	1,197	(8.7)	4,800	7,218	(33.5)
EBITDA	2,368	1,987	19.2	2,601	(8.9)	9,334	7,083	31.8
EBITDA margin (%)	15.2	13.4	180bps	17.1	-198bps	15.0	12.5	245bps
Finance expenses	132	144	(8.4)	109	20.5	562	502	12.0
Depreciation	690	662	4.3	695	(0.6)	2,727	2,754	(1.0)
Other income	21	117	(82.0)	36	(41.7)	283	27	933.2
PBT	1,567	1,298	20.7	1,832	(14.5)	6,313	3,546	78.1
Ταχ	225	92	145.8	46	384.7	160	126	26.9
Effective tax rate (%)	14.4	7.0	730bps	2.5	1182bps	2.5	3.6	-102bps
Reported PAT	1,345	1,206	11.5	1,782	(24.5)	6,153	3,420	79.9
Adj PAT	1,345	1,206	11.5	1,782	(24.5)	6,153	3,420	79.9
EPS (INR)	6.8	6.1	11.5	9.1	(24.5)	31.3	17.4	79.9


Source: I-Sec research, Company data

Exhibit 2: Business mix


Particulars (INR mn)	Q1FY25	Q1FY24	%YoY	Q4FY24	%QoQ	FY24	FY23	%YoY
Formulation	13,040	11,800	10.5	11,880	9.8	49,820	44,870	11.0
Domestic	5,720	5,240	9.2	5,030	13.7	22,000	20,630	6.6
% of sales	36.6	35.3		33.1		35.3	36.5	
US	4,610	3,900	18.2	4,230	9.0	17,300	15,720	10.1
% of sales	29.5	26.3		27.9		27.8	27.8	
Other international markets	2,710	2,660	1.9	2,620	3.4	10,520	8,520	23.5
% of sales	17.3	17.9		17.3		16.9	15.1	
API	2,590	3,050	(15.1)	3,300	(21.5)	12,460	11,660	6.9
% of sales	16.6	20.5		21.7		20.0	20.6	
TOTAL	15,630	14,850	5.3	15,180	3.0	62,280	56,530	10.2

Source: I-Sec research, Company data

Exhibit 3: Launched 2 new products in Q1FY25




Source: I-Sec research, Company data




Source: I-Sec research, Company data

Exhibit 7: API business declined due to pricing pressure




Source: I-Sec research, Company data

Exhibit 4: Launches to drive 10.4% CAGR over FY24-26E




Source: I-Sec research, Company data

Exhibit 6: India biz to register ~7.6% CAGR over FY24-26E



Source: I-Sec research, Company data


Exhibit 8: API biz to grow at 4.9% over FY24-26E



Source: I-Sec research, Company data









Source: I-Sec research, Company data

Exhibit 11: Gross margin expanded by 259bps YoY




Source: I-Sec research, Company data

Exhibit 13: EBITDA margin expanded 180bps YoY on the account of lower R&D cost




Source: I-Sec research, Company data

Exhibit 10: Revenue likely to register 9% CAGR over FY24-26E



Source: I-Sec research, Company data

Exhibit 12: Stability in India and US to comfort margins



Source: I-Sec research, Company data




Exhibit 14: Cost curtailment to boost 260bps expansion in

Source: I-Sec research, Company data

margins over FY24-26E




Exhibit 15: Shareholding pattern

%	Dec'23	Mar'24	Jun'24
Promoters	69.6	69.6	69.6
Institutional investors	19.0	19.8	19.8
MFs and others	7.7	7.8	8.1
Fls/Banks	0.0	0.0	0.4
Insurance	6.5	7.1	7.0
FIIs	4.8	4.9	4.3
Others	11.4	10.6	10.6

Source: Bloomberg

Exhibit 16: Price chart



Source: Bloomberg



Financial Summary

Exhibit 17: Profit & Loss

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Net Sales	56,526	62,286	67,840	74,048
Operating Expenses	49,443	52,953	56,850	61,016
EBITDA	7,083	9,334	10,990	13,032
EBITDA Margin (%)	12.5	15.0	16.2	17.6
Depreciation & Amortization	2,754	2,727	3,007	3,308
EBIT	4,329	6,607	7,983	9,724
Interest expenditure	502	562	275	87
Other Non-operating	27	283	133	271
Income	27	205	122	2/1
Recurring PBT	3,855	6,328	7,842	9,908
Profit / (Loss) from	(200)	(10)	(10)	(10)
Associates	(309)	(10)	(10)	(10)
Less: Taxes	126	160	1,331	1,683
PAT	3,729	6,168	6,510	8,225
Less: Minority Interest	-	-	-	-
Extraordinaries (Net)	-	-	-	-
Net Income (Reported)	3,420	6,158	6,500	8,215
Net Income (Adjusted)	3,420	6,158	6,500	8,215

Source Company data, I-Sec research

Exhibit 18: Balance sheet

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Total Current Assets	29,100	30,786	34,343	39,534
of which cash & cash eqv.	823	1,266	2,222	4,510
Total Current Liabilities & Provisions	10,011	10,245	10,963	11,736
Net Current Assets	19,090	20,540	23,380	27,798
Investments	963	930	938	945
Net Fixed Assets	29,997	30,711	30,704	30,395
ROU Assets	-	-	-	-
Capital Work-in-Progress	-	-	-	-
Total Intangible Assets	537	333	350	367
Other assets	1,230	1,696	1,696	1,696
Deferred Tax Assets	-	-	-	-
Total Assets	51,818	54,210	57,067	61,202
Liabilities				
Borrowings	7,051	4,933	2,933	929
Deferred Tax Liability	-	-	-	-
provisions	1,062	1,095	1,095	1,095
other Liabilities	-	-	-	-
Equity Share Capital	393	393	393	393
Reserves & Surplus	43,312	47,789	52,646	58,785
Total Net Worth	43,705	48,182	53,039	59,178
Minority Interest	-	-	-	-
Total Liabilities	51,818	54,210	57,067	61,202

Source Company data, I-Sec research

Exhibit 19: Cashflow statement

(INR mn, year ending March)

	FY23A	FY24A	FY25E	FY26E
Operating Cashflow	4,482	7,891	7,749	9,192
Working Capital Changes	2,905	2,258	770	1,900
Capital Commitments	(8,561)	3,440	3,000	3,000
Free Cashflow	13,043	4,451	4,749	6,192
Other investing cashflow	1,009	433	7	8
Cashflow from Investing Activities	7,552	(3,873)	(3,007)	(3,008)
Issue of Share Capital	-	-	-	-
Interest Cost	-	-	-	-
Inc (Dec) in Borrowings	751	(2,118)	(2,000)	(2,004)
Dividend paid	(1,893)	(2,602)	(1,643)	(2,076)
Others	(10,764)	1,146	(142)	183
Cash flow from Financing Activities	(11,906)	(3,574)	(3,785)	(3,897)
Chg. in Cash & Bank balance	128	443	956	2,288
Closing cash & balance	823	1,266	2,222	4,510

Source Company data, I-Sec research

Exhibit 20: Key ratios

(Year ending March)

	FY23A	FY24A	FY25E	FY26E
Per Share Data (INR)				
Reported EPS	17.4	31.3	33.1	41.8
Adjusted EPS (Diluted)	17.4	31.3	33.1	41.8
Cash EPS	31.4	45.2	48.4	58.6
Dividend per share (DPS)	9.6	13.2	8.4	10.6
Book Value per share (BV)	222.4	245.1	269.9	301.1
Dividend Payout (%)	55.3	42.3	25.3	25.3
Growth (%)				
Net Sales	6.5	10.2	8.9	9.2
EBITDA	(19.0)	31.8	17.7	18.6
EPS (INR)	(37.3)	80.1	5.6	26.4
Valuation Ratios (x)				
P/E	69.8	38.7	36.7	29.0
P/CEPS	38.6	26.9	25.1	20.7
P/BV	5.5	5.0	4.5	4.0
EV / EBITDA	34.4	25.9	21.7	18.0
P / Sales	4.2	3.8	3.5	3.2
Dividend Yield (%)	0.0	0.0	0.0	0.0
Operating Ratios				
Gross Profit Margins (%)	69.8	72.5	73.5	73.7
EBITDA Margins (%)	12.5	15.0	16.2	17.6
Effective Tax Rate (%)	3.3	2.5	17.0	17.0
Net Profit Margins (%)	6.0	9.9	9.6	11.1
NWC / Total Assets (%)	-	-	-	-
Net Debt / Equity (x)	0.1	0.1	0.0	(0.1)
Net Debt / EBITDA (x)	0.7	0.3	0.0	(0.3)
Profitability Ratios				
RoCE (%)	7.7	12.9	12.4	14.3
RoE (%)	7.1	13.4	12.8	14.6
RoIC (%)	8.5	13.1	12.7	15.1
Fixed Asset Turnover (x)	2.7	2.5	2.6	2.7
Inventory Turnover Days	98	101	100	101
Receivables Days	70	63	63	63
Payables Days	45	45	44	44
Source Company data Soc reco				

Source Company data, I-Sec research



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return;

ANALYST CERTIFICATION

I/We, Abdulkader Puranwala MBA (Finance); Nisha Shetty, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ00183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report. ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing

requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it

is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, **E-mail Address** : <u>complianceofficer@icicisecurities.com</u> For any queries or grievances: <u>Mr. Bhavesh Soni</u> Email address: <u>headservicequality@icicidirect.com</u> Contact Number: 18601231122